Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Non-Current Assets (2020 - 2025)

Candel Therapeutics' Non-Current Assets history spans 4 years, with the latest figure at $4.4 million for Q4 2023.

  • On a quarterly basis, Non-Current Assets fell 23.36% to $4.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was $20.1 million, a 14.85% decrease, with the full-year FY2023 number at $4.4 million, down 23.36% from a year prior.
  • Non-Current Assets hit $4.4 million in Q4 2023 for Candel Therapeutics, down from $5.0 million in the prior quarter.
  • Over the last five years, Non-Current Assets for CADL hit a ceiling of $6.3 million in Q2 2021 and a floor of $3.1 million in Q4 2020.
  • Historically, Non-Current Assets has averaged $5.2 million across 4 years, with a median of $5.4 million in 2023.
  • Biggest five-year swings in Non-Current Assets: soared 35.84% in 2021 and later dropped 23.36% in 2023.
  • Tracing CADL's Non-Current Assets over 4 years: stood at $3.1 million in 2020, then soared by 35.84% to $4.3 million in 2021, then surged by 34.88% to $5.7 million in 2022, then fell by 23.36% to $4.4 million in 2023.
  • Business Quant data shows Non-Current Assets for CADL at $4.4 million in Q4 2023, $5.0 million in Q3 2023, and $5.3 million in Q2 2023.